Seiji Kishi

Seiji Kishi

Auto-generated profile, based on publicly available information

Seiji Kishi

Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Japan

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2023 in Nature Reviews Nephrology
Verified
Journal Article
Closed access
PDF file
SKSeiji Kishi
Seiji Kishi
HNHajime Nagasu
Hajime Nagasu
KKKengo Kidokoro
Kengo Kidokoro
NKNaoki Kashihara
Naoki Kashihara

23 January 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
GCGuillaume Canaud
Guillaume Canaud
CBCraig R. Brooks
Craig R. Brooks
SKSeiji Kishi
Seiji Kishi
KTkensei taguchi
kensei taguchi
KNKenji Nishimura
Kenji Nishimura
JBJoseph V Bonventre
Joseph V Bonventre
Cyclin G1 regulates G 2 -M arrest in proximal tubular cells, promoting a TASCC-induced secretory phenotype, fibrosis, and kidney disease progression.

7 October 2019 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
SKSeiji Kishi
Seiji Kishi
CBCraig R. Brooks
Craig R. Brooks
KTkensei taguchi
kensei taguchi
TITakaharu Ichimura
Takaharu Ichimura
YMYutaro Mori
Yutaro Mori
JBJoseph V Bonventre
Joseph V Bonventre
Maladaptive proximal tubule (PT) repair has been implicated in kidney fibrosis through induction of cell-cycle arrest at G2/M. We explored the relative importance of the PT DNA damage response (DDR) in kidney fibrosis by genetically inactivating ataxia telangiectasia and Rad3-related (ATR), which is a sensor and upstream initiator of the DDR. In human chronic kidney disease, ATR expression inversely correlates with DNA damage. ATR was upregulated in approximately 70% of Lotus tetragonolobus lectin-positive (LTL+) PT cells in cisplatin-exposed human kidney organoids. Inhibition of ATR resulted in greater PT cell injury in organoids and cultured PT cells. PT-specific Atr-knockout (ATRRPTC-/-) mice exhibited greater kidney function impairment, DNA damage, and fibrosis than did WT mice in response to kidney injury induced by either cisplatin, bilateral ischemia-reperfusion, or unilateral ureteral obstruction. ATRRPTC-/- mice had more cells in the G2/M phase after injury than did WT mice after similar treatments. In conclusion, PT ATR activation is a key component of the DDR, which confers a protective effect mitigating the maladaptive repair and consequent fibrosis that follow kidney injury.

8 July 2024 in Nature Reviews Nephrology
Verified
Journal Article
Closed access
PDF file
SKSeiji Kishi
Seiji Kishi
HKHiroyuki Kadoya
Hiroyuki Kadoya
NKNaoki Kashihara
Naoki Kashihara

9 November 2024 in Kidney International Reports
Verified
Journal Article
Open access
MTMasanobu Takasu
Masanobu Takasu
SKSeiji Kishi
Seiji Kishi
HNHajime Nagasu
Hajime Nagasu
KKKengo Kidokoro
Kengo Kidokoro
CBCraig R. Brooks
Craig R. Brooks
NKNaoki Kashihara
Naoki Kashihara
Diabetic kidney disease (DKD) is recognized worldwide as a leading cause of end-stage renal failure. Although therapies that target glomerular hemodynamics and can inhibit disease progression have been developed, there is currently no fundamental cure for the disease. Mitochondria play an important role in cellular respiration, producing adenosine triphosphate (ATP) by oxidative phosphorylation, and are essential for renal function, especially in proximal tubular cells (PTCs). In diabetic conditions, maintaining mitochondrial health is vital for preserving renal function. Under diabetic conditions, excessive reactive oxygen species (ROS) can damage mitochondrial DNA (mtDNA), leading to renal dysfunction. Strategies targeting mitochondrial function, such as AMP-activated protein kinase (AMPK) activation and modulation of nitric oxide (NO) availability, are promising for suppressing diabetic nephropathy. The immune response to DKD, initiated by detecting damage- and pathogen-associated molecular patterns, has a significant impact on the progression of DKD, including leakage of mtDNA and RNA, leading to inflammation through various pathways. This contributes to renal impairment characterized by hyperfiltration, endothelial dysfunction, and albuminuria. Mitochondrial energy metabolism and dynamics induced by hyperglycemia precede the onset of albuminuria and histological changes in the kidneys. The increased mitochondrial fission and decreased fusion that occur under diabetic conditions result in ATP depletion and exacerbate cellular dysfunction. Therapeutic strategies focused on restoring mitochondrial function are promising for slowing the progression of DKD and reduce the adverse effects on renal function. Sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 (GLP-1) receptor agonists, already in clinical use, have been shown to be protective for mitochondria, and nuclear factor erythroid 2-related factor 2 (Nrf2) activation and mitochondrial dynamics are promising drug discovery targets for further research.

1 June 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
HAHideharu Abe
Hideharu Abe
TTTatsuya Tominaga
Tatsuya Tominaga
TMTakeshi Matsubara
Takeshi Matsubara
NANaoko Abe
Naoko Abe
SKSeiji Kishi
Seiji Kishi
TDToshio Doi
Toshio Doi
Activation of mesangial cells (MCs), which is characterized by induction of smooth muscle α-actin (SMA) expression, contributes to a key event in various renal diseases; however, the mechanisms controlling MC differentiation are still largely undefined. Activated Smad1 induced SMA in a dose-dependent manner in MCs. As a direct regulating molecule for SMA, we identified and characterized scleraxis (Scx) as a new phenotype modulator in advanced glycation end product (AGE)-exposed MCs. Scx physically associated with E12 and bound the E-box in the promoter of SMA and negatively regulated the AGE-induced SMA expression. Scx induced expression and secretion of bone morphogenetic protein 4 (BMP4), thereby controlling the Smad1 activation in AGE-treated MCs. In diabetic mice, Scx was concomitantly expressed with SMA in the glomeruli. Inhibitor of differentiation 1 (Id1) was further induced by extended treatment with AGE, thereby dislodging Scx from the SMA promoter. These data suggest that Scx and Id1 are involved in the BMP4-Smad1-SMA signal transduction pathway besides the TGFβ1-Smad1-SMA signaling pathway and modulate phenotypic changes in MCs in diabetic nephropathy.